<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035277</url>
  </required_header>
  <id_info>
    <org_study_id>247400</org_study_id>
    <secondary_id>2021-001554-61</secondary_id>
    <nct_id>NCT05035277</nct_id>
  </id_info>
  <brief_title>AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation</brief_title>
  <acronym>ACASA-TAVI</acronym>
  <official_title>AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      ACASA-TAVI is a pragmatic randomized controlled trial assessing the value of anticoagulation&#xD;
      therapy versus the standard antiplatelet therapy after transcatheter aortic valve&#xD;
      implantation in patients with aortic stenosis. The trial will assess the efficacy of direct&#xD;
      oral anticoagulation (DOAC) therapy compared to the standard single antiplatelet therapy to&#xD;
      prevent degeneration of the valve and its safety in co-primary endpoints with blinded&#xD;
      endpoint adjudication. The effect of DOAC therapy on hard clinical outcomes will be assessed&#xD;
      during long-term follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aortic stenosis is a highly prevalent valvular disease and an important cause of morbidity&#xD;
      and mortality in the elderly population. Transcatheter aortic valve implantation (TAVI) is an&#xD;
      effective intervention in patients with severe aortic stenosis and low surgical risk. The&#xD;
      procedure is highly effective, safe, and widely implemented. Current recommendations support&#xD;
      transcatheter treatment of younger patients, including patients from 65 years of age with low&#xD;
      surgical risk. This practice increases the importance of long-term valve maintenance.&#xD;
&#xD;
      Observational data have suggested that early signs of valve degeneration (i.e.&#xD;
      hypo-attenuated leaflet thickening/thrombosis/reduced leaflet motion) are associated with an&#xD;
      increased risk of embolic events. This is an increasing problem with emerging indications in&#xD;
      younger populations. Because both ischemic and bleeding complications after TAVI can be&#xD;
      life-threatening, it is important to establish the optimal anti-thrombotic treatment regime.&#xD;
      Use of oral anticoagulation after implantation for bioprosthetic valves have been associated&#xD;
      with resolved valve degeneration and possible favourable clinical effects.&#xD;
&#xD;
      The current practice guidelines recommend that oral anticoagulation may be considered for 3&#xD;
      months after open surgical bioprosthetic valve implantation. Patients with an independent&#xD;
      indication for oral anticoagulation (i.e. atrial fibrillation or venous thromboembolism) are&#xD;
      recommended to continue this treatment lifelong, but there is no recommendation for oral&#xD;
      anticoagulation following TAVI in patients without other indications. In patients without&#xD;
      indication for oral anticoagulation, the use of double anti-platelet therapy for 3-6 months&#xD;
      following TAVI is recommended. However, single anti-platelet therapy with acetylsalicylic&#xD;
      acid (ASA) without clopidogrel has been reported to improve bleeding outcomes and a composite&#xD;
      of bleeding and ischemic outcomes. The effect of on oral anticoagulation-based treatment&#xD;
      strategy compared to the standard single anti-platelet treatment strategy for valve&#xD;
      maintenance after TAVI is unknown.&#xD;
&#xD;
      Increased anti-thrombotic treatment intensity may come at the cost of increased bleeding&#xD;
      risk. Dual anti-platelet therapy and combination therapy with anticoagulation and&#xD;
      anti-platelet therapy have both been associated with unfavourable outcomes. Combined&#xD;
      anti-platelet and anti-coagulation treatment has been shown to reduce valve degeneration at&#xD;
      the cost of increased bleeding. Conversely, single anti-platelet therapy and anti-coagulation&#xD;
      with a direct oral anti-coagulant (DOAC) have been associated with similar bleeding risk.&#xD;
      Bleeding rates in patients treated with anti-coagulation after TAVI have been reported to be&#xD;
      slightly higher than in patients treated with ASA after TAVI, but patients with conventional&#xD;
      indications for anti-coagulation have higher baseline bleeding risk than those without such&#xD;
      indications. Therefore, the risk of bleeding in patients treated with DOAC or ASA following&#xD;
      TAVI may be similar, but no randomized trials have been performed.&#xD;
&#xD;
      ACASA-TAVI will include 360 patients &gt; 65 years and &lt; 80 years of age who have undergone&#xD;
      successful TAVI and have no conventional indication for DOAC in a prospective randomized&#xD;
      open-label blinded-endpoint (PROBE) study. The intervention arm will be 12 month therapy with&#xD;
      an anti-Xa type DOAC (without antiplatelet therapy) and the active control arm will be&#xD;
      standard dose ASA. After 12 months, the intervention group will be switched to ASA&#xD;
      maintenance. All patients will undergo clinical assessment, cardiac CT and echocardiography&#xD;
      at 12 months with blinded endpoint adjudication by an independent committee.&#xD;
&#xD;
      Outcome measures will comply with the Valve Academic Research Consortium 3 (VARC-3)&#xD;
      consensus, and are described in detail in the protocol. The co-primary endpoints at 12&#xD;
      months, hypo-attenuated leaflet thickening (HALT) and safety composite, must both be met for&#xD;
      the trial to declare success.&#xD;
&#xD;
      The effect of the DOAC therapy on long-term major adverse cardiovascular events (MACE) will&#xD;
      be assessed after 5 years and 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel group prospective randomized open blinded endpoint (PROBE) trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Separate endpoint adjudication committee blinded to randomized allocation of patients to treatment groups</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hypo-attenuated leaflet thickening</measure>
    <time_frame>12 months</time_frame>
    <description>First co-primary endpoint. The presence of hypo-attenuated leaflet thickening on dedicated cardiac CT after 12 months will be registered by a blinded expert reader. Intention-to-treat, superiority.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety composite - Incidence of Treatment Emergent Adverse Clinical Outcome</measure>
    <time_frame>12 months</time_frame>
    <description>Second co-primary outcome. Composite of VARC-3 bleeding events, thromboembolic events (myocardial infarction or stroke) and all-cause mortality. Per-protocol, non-inferiority.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse cardiovascular events (MACE)</measure>
    <time_frame>5 years</time_frame>
    <description>Primary outcome during long-term follow-up. The rate of the composite of Cardiac death, Aortic valve re-intervention, Stroke, Myocardial infarction, Heart failure hospitalization and Major, life-threatening, or disabling bleeding.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse cardiovascular events (MACE)</measure>
    <time_frame>10 years</time_frame>
    <description>Primary outcome during long-term follow-up. The rate of the composite of Cardiac death, Aortic valve re-intervention, Stroke, Myocardial infarction, Heart failure hospitalization and Major, life-threatening, or disabling bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>First hierarchical secondary outcome. Composite of of Freedom from all-cause mortality, Freedom from all stroke, Freedom from hospitalization for procedure- or valve-related causes, Freedom from KCCQ overall summary score &lt;45 or decline from baseline of &gt;10 points. Intention-to-treat, superiority.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety composite, superiority</measure>
    <time_frame>12 months</time_frame>
    <description>Second hierarchical secondary outcome. Composite of VARC-3 bleeding events, thromboembolic events (myocardial infarction or stroke) and all-cause mortality. Same endpoint as second co-primary outcome, but intention-to-treat, superiority.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic events</measure>
    <time_frame>12 months</time_frame>
    <description>Third hierarchical secondary outcome. Composite of myocardial infarction or stroke of any cause. Intention-to-treat population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>12 months</time_frame>
    <description>Fourth hierarchical secondary outcome. Bleeding events according to VARC-3 definitions. Intention-to-treat population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Fifth hierarchical secondary outcome. Intention-to-treat population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>First secondary safety endpoint. Safety population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of serious adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Second secondary safety endpoint. Safety population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life-threatening or disabling bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Third secondary safety endpoint. Safety population. VARC-3 definition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Fourth secondary safety endpoint. Safety population. VARC-3 definition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Fifth secondary safety endpoint. Safety population. VARC-3 definition.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CT signs of valve degeneration</measure>
    <time_frame>12 months</time_frame>
    <description>Exploratory outcome. Any evidence of reduced leaflet mobility, hypo-attenuated leaflet thickening or thrombus.</description>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiographic signs of valve degeneration</measure>
    <time_frame>12 months</time_frame>
    <description>Exploratory outcome. Change in transaortic pressure gradient assessed by echocardiography.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac function</measure>
    <time_frame>12 months</time_frame>
    <description>Exploratory outcome. Change in left ventricular global longitudinal strain assessed by echocardiography.</description>
  </other_outcome>
  <other_outcome>
    <measure>Non-procedure-related life-threatening or disabling bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Exploratory outcome. VARC-3 definition.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of major adverse clinical events</measure>
    <time_frame>12 months</time_frame>
    <description>Exploratory outcome. Defined as stroke or transient ischemic attack of any cause, myocardial infarction, re-intervention on the aortic valve, death (cardiac, all-cause, non-cardiac) and heart failure hospitalization</description>
  </other_outcome>
  <other_outcome>
    <measure>Troponin T</measure>
    <time_frame>12 months</time_frame>
    <description>Exploratory outcome. Assessment of blood samples.</description>
  </other_outcome>
  <other_outcome>
    <measure>N-terminal pro-B-type natriuretic peptide</measure>
    <time_frame>12 months</time_frame>
    <description>Exploratory outcome. Assessment of blood samples.</description>
  </other_outcome>
  <other_outcome>
    <measure>Infective endocarditis</measure>
    <time_frame>12 months</time_frame>
    <description>Exploratory outcome. Definition by Duke criteria.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in quality of life - Kansas City Cardiomyopathy Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Exploratory outcome. Assessed by change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (score 0-100, Higher value indicates better quality of life).</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive function</measure>
    <time_frame>12 months</time_frame>
    <description>Exploratory outcome. Assessed by change in the Mini-cog score</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical efficacy</measure>
    <time_frame>5 years</time_frame>
    <description>Composite of of Freedom from all-cause mortality, Freedom from all stroke, Freedom from hospitalization for procedure- or valve-related causes, Freedom from KCCQ overall summary score &lt;45 or decline from baseline of &gt;10 points. Intention-to-treat, superiority.</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Fifth hierarchical secondary outcome. Intention-to-treat population.</description>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiographic signs of valve degeneration</measure>
    <time_frame>5 years</time_frame>
    <description>Exploratory outcome. Change in transaortic pressure gradient assessed by echocardiography.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac function</measure>
    <time_frame>5 years</time_frame>
    <description>Exploratory outcome. Change in left ventricular global longitudinal strain assessed by echocardiography.</description>
  </other_outcome>
  <other_outcome>
    <measure>N-terminal pro-B-type natriuretic peptide</measure>
    <time_frame>5 years</time_frame>
    <description>Exploratory outcome. Assessment of blood samples.</description>
  </other_outcome>
  <other_outcome>
    <measure>Troponin T</measure>
    <time_frame>5 years</time_frame>
    <description>Exploratory outcome. Assessment of blood samples.</description>
  </other_outcome>
  <other_outcome>
    <measure>Individual components of MACE</measure>
    <time_frame>5 years</time_frame>
    <description>Exploratory outcome. Assessment of the individual components of MACE (the primary outcome at long-term follow-up).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in quality of life - Kansas City Cardiomyopathy Questionnaire</measure>
    <time_frame>5 years</time_frame>
    <description>Exploratory outcome. Assessed by change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (score 0-100, Higher value indicates better quality of life).</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive function</measure>
    <time_frame>5 years</time_frame>
    <description>Exploratory outcome. Assessed by change in the Mini-cog score</description>
  </other_outcome>
  <other_outcome>
    <measure>Infective endocarditis</measure>
    <time_frame>5 years</time_frame>
    <description>Exploratory outcome. Definition by Duke criteria.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical efficacy</measure>
    <time_frame>10 years</time_frame>
    <description>Composite of of Freedom from all-cause mortality, Freedom from all stroke, Freedom from hospitalization for procedure- or valve-related causes, Freedom from KCCQ overall summary score &lt;45 or decline from baseline of &gt;10 points. Intention-to-treat, superiority.</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>10 years</time_frame>
    <description>Fifth hierarchical secondary outcome. Intention-to-treat population.</description>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiographic signs of valve degeneration</measure>
    <time_frame>10 years</time_frame>
    <description>Exploratory outcome. Change in transaortic pressure gradient assessed by echocardiography.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac function</measure>
    <time_frame>10 years</time_frame>
    <description>Exploratory outcome. Change in left ventricular global longitudinal strain assessed by echocardiography.</description>
  </other_outcome>
  <other_outcome>
    <measure>N-terminal pro-B-type natriuretic peptide</measure>
    <time_frame>10 years</time_frame>
    <description>Exploratory outcome. Assessment of blood samples.</description>
  </other_outcome>
  <other_outcome>
    <measure>Troponin T</measure>
    <time_frame>10 years</time_frame>
    <description>Exploratory outcome. Assessment of blood samples.</description>
  </other_outcome>
  <other_outcome>
    <measure>Individual components of MACE</measure>
    <time_frame>10 years</time_frame>
    <description>Exploratory outcome. Assessment of the individual components of MACE (the primary outcome at long-term follow-up).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in quality of life - Kansas City Cardiomyopathy Questionnaire</measure>
    <time_frame>10 years</time_frame>
    <description>Exploratory outcome. Assessed by change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (score 0-100, Higher value indicates better quality of life).</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive function</measure>
    <time_frame>10 years</time_frame>
    <description>Exploratory outcome. Assessed by change in the Mini-cog score</description>
  </other_outcome>
  <other_outcome>
    <measure>Infective endocarditis</measure>
    <time_frame>10 years</time_frame>
    <description>Exploratory outcome. Definition by Duke criteria.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Acetylsalicylic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the active control arm will receive 75 mg acetylsalicylic acid once daily indefinitely.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Direct oral anticoagulation (DOAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental arm will receive an anti Xa-type DOAC (apixaban, rivaroxaban or edoxaban) in approved therapeutic dose for 12 months. The choice of DOAC agent will be made by the treating clinician after discussion with the patient. After 12 months, these patients will abort DOAC therapy. Acetylsalicylic acid, 75 mg once daily will be started after DOAC discontinuation and continued indefinitely.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>Acetylsalicylic acid 75 mg once daily is the current standard-of-care in TAVI patients without other indications for anticoagulation therapy.</description>
    <arm_group_label>Acetylsalicylic acid</arm_group_label>
    <other_name>B01A C06</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Standard dose apixaban will be one of the options for the patients in the experimental arm.</description>
    <arm_group_label>Direct oral anticoagulation (DOAC)</arm_group_label>
    <other_name>B01A F02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Standard dose rivaroxaban will be one of the options for the patients in the experimental arm.</description>
    <arm_group_label>Direct oral anticoagulation (DOAC)</arm_group_label>
    <other_name>B01A F01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>Standard dose edoxaban will be one of the options for the patients in the experimental arm.</description>
    <arm_group_label>Direct oral anticoagulation (DOAC)</arm_group_label>
    <other_name>B01A F03</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Successful trans-catheter aortic valve implantation in patients aged &gt;65 and &lt;80 years&#xD;
             old at the time of the procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Strict indication for anticoagulation or anti-platelet drugs&#xD;
&#xD;
          -  Strict contraindication for anticoagulation or anti-platelet drugs&#xD;
&#xD;
          -  Overt cognitive failure&#xD;
&#xD;
          -  Failure to obtain written informed consent&#xD;
&#xD;
          -  Concomitant use of inducers or inhibitors of CYP3A4 or P-glycoprotein&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Øyvind H Lie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Øyvind H Lie, MD, PhD</last_name>
    <phone>+4793429011</phone>
    <email>oyvlie@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>VARC-3 WRITING COMMITTEE, Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, Bax JJ, Leipsic JA, Blanke P, Blackstone EH, Finn MT, Kapadia S, Linke A, Mack MJ, Makkar R, Mehran R, Popma JJ, Reardon M, Rodes-Cabau J, Van Mieghem NM, Webb JG, Cohen DJ, Leon MB. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021 May 14;42(19):1825-1857. doi: 10.1093/eurheartj/ehaa799.</citation>
    <PMID>33871579</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Øyvind Lie</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Transcatheter Aortic Valve Implantation</keyword>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>Antithrombotic therapy</keyword>
  <keyword>Anticoagulation therapy</keyword>
  <keyword>Antiplatelet therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The application to share IPD is pending with the ethical committee.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Will be made available with the publication of the primary analysis and remain available for 1 year. Thereafter, it can be made available upon request.</ipd_time_frame>
    <ipd_access_criteria>Researchers and clinicians with valid medical questions to be addressed. The data will not be available for commercial use.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 17, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT05035277/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

